17.4 Complementary, Alternative & Integrative Therapies in Oncology
Key Takeaways
Up to 30-50% of patients with cancer use complementary approaches, usually without disclosing them; nonjudgmental supplement histories are a mandatory part of oncology medication reconciliation.
St. John's Wort potently induces CYP3A4 and P-glycoprotein, cutting exposure to oral oncolytics (imatinib, venetoclax, CDK4/6 inhibitors, irinotecan) and must be stopped with a washout before therapy; grapefruit inhibits CYP3A4 and raises TKI toxicity risk.
High-dose antioxidant supplements (vitamins C, E, beta-carotene) are discouraged during radiation and ROS-dependent chemotherapy because ROS scavenging can antagonize treatment; SELECT and CARET linked vitamin E and beta-carotene supplements to increased cancer risk.
ASCO-SIO integrative oncology guidelines support acupuncture/acupressure, mindfulness, massage, and music therapy as adjuncts for CINV, pain, anxiety, and fatigue; ginger, cannabinoids, and acetyl-L-carnitine must not replace guideline-directed antiemetic or neuropathy care.
Substituting alternative therapy for curative treatment approximately doubles cancer mortality; pharmacists counsel with authoritative resources (NCI PDQ, MSKCC About Herbs, NCCIH) and document every supplement decision.
1. Definitions, Prevalence & the Disclosure Gap
Blueprint task 2B7 (Complementary and Alternative Therapies) expects the oncology pharmacist to manage patients who use non-conventional therapies safely and without judgment. Complementary therapies are used alongside conventional treatment (e.g., acupuncture for nausea); alternative therapies are used instead of it; integrative oncology coordinates evidence-informed complementary modalities with conventional care. Surveys consistently show 30-50% of patients with cancer use some form of complementary approach, and the majority do not spontaneously disclose it to their oncology team — often because they fear disapproval. Every oncology medication reconciliation must therefore explicitly probe for vitamins, minerals, herbs, teas, and "natural" products.
2. Pharmacokinetic & Pharmacodynamic Interactions (High-Yield Table)
| Product | Mechanism | Clinical Consequence | Action |
|---|---|---|---|
| St. John's Wort | Potent CYP3A4 / CYP2C19 / P-glycoprotein inducer | Slashes exposure to imatinib, venetoclax, CDK4/6 inhibitors, irinotecan (SN-38 AUC down ~40%), docetaxel -> subtherapeutic treatment failure | Discontinue (allow ~2-week washout) before oral oncolytics |
| Grapefruit / Seville orange / pomelo | Intestinal CYP3A4 inhibition | Raises exposure to many TKIs and oral agents -> toxicity | Avoid during therapy with narrow-index CYP3A4 substrates |
| Green tea extract (EGCG) | Catechin binds the boronic acid of bortezomib (in vitro) | May antagonize proteasome inhibitor activity | Discourage concentrated extracts during bortezomib; dietary tea in moderation is acceptable |
| High-dose biotin | Interferes with streptavidin-biotin immunoassays | Falsely LOW troponin/PSA/beta-hCG; falsely high free T4 -> misinterpreted monitoring and emergencies | Hold >=48-72 hours before laboratory draws |
| Garlic, ginkgo, high-dose fish oil, curcumin | Antiplatelet / anticoagulant potentiation | Bleeding risk with surgery, thrombocytopenia, or anticoagulation | Stop before procedures and during severe thrombocytopenia |
| Milk thistle (silymarin) | Weak CYP2C9/3A4 modulation | Minor interaction potential; generally tolerated | Monitor; document |
| Echinacea / "immune boosters" | Immunostimulation | Theoretical antagonism of immunosuppression; caution around checkpoint-inhibitor irAE management | Counsel on uncertainty; document |
| Kava, comfrey | Direct hepatotoxicity | Additive liver injury with hepatotoxic regimens | Avoid |
3. Antioxidants, Phytoestrogens & Treatment-Antagonism Controversies
- High-dose antioxidant supplements (vitamins C and E, beta-carotene, N-acetylcysteine) are discouraged during radiation therapy and ROS-dependent cytotoxic regimens (anthracyclines, platinums, alkylators) because reactive-oxygen-species scavenging may blunt treatment mechanisms; the SELECT trial linked vitamin E supplementation to increased prostate cancer risk, and CARET linked beta-carotene to increased lung cancer in smokers.
- Soy/phytoestrogens in ER-positive breast cancer: moderate dietary intake appears safe and possibly beneficial; concentrated isoflavone supplements should be discouraged pending better data.
- Laetrile ("vitamin B17") is ineffective and causes cyanide toxicity; high-dose IV vitamin C has no proven survival benefit and risks oxalate nephropathy and G6PD hemolysis; mistletoe extracts lack rigorous efficacy evidence and interact unpredictably.
- "Alternative instead of curative" harm: observational data show patients who substitute alternative medicine for conventional curative cancer treatment have roughly double the risk of death; the pharmacist's role is respectful redirection, never ridicule.
A 61-year-old patient with chronic-phase CML achieving a deep molecular response on imatinib 400 mg daily reports starting St. John's Wort 300 mg three times daily last month for low mood. Quantitative BCR::ABL1 transcripts have risen from 0.02% to 0.9% (IS). What is the most likely pharmacologic explanation and appropriate action?
St. John's Wort inhibits CYP3A4, causing imatinib accumulation and paradoxical transcript rebound; double the imatinib dose
The transcript rise is random laboratory variation; continue both agents and recheck in 6 months
St. John's Wort induces CYP3A4/P-glycoprotein, accelerating imatinib clearance and producing subtherapeutic exposure and molecular relapse; discontinue the supplement (allowing washout) and recheck transcripts
St. John's Wort chelates imatinib in the gut; separate the doses by 2 hours and continue both
4. Evidence-Supported Integrative Modalities (ASCO-SIO Guidelines)
The joint ASCO-Society for Integrative Oncology guidelines distinguish helpful adjuncts from unsupported substitutes:
- Recommended adjuncts: acupuncture and acupressure (chemotherapy-induced nausea/vomiting adjunct, cancer pain, hot flashes, xerostomia), mindfulness/yoga (anxiety, depression, fatigue), massage therapy (anxiety, pain — gentle technique, avoid tumor sites and lymphedema limbs), music therapy, hypnosis (procedural pain and anxiety).
- Insufficient or negative evidence: ginger is not a substitute for guideline antiemetic prophylaxis (5-HT3 + NK1 + dexamethasone +/- olanzapine); acetyl-L-carnitine should be avoided for chemotherapy-induced peripheral neuropathy (worsened neuropathy in a randomized trial); oral glutamine evidence is inconsistent.
5. Cannabis & Cannabinoids
- Dronabinol and nabilone are FDA-approved for refractory chemotherapy-induced nausea and vomiting — they are rescue agents, not replacements for first-line prophylaxis.
- Cannabidiol (CBD) is metabolized by and inhibits CYP2C19 and CYP3A4 (drug interactions with TKIs and other narrow-index agents), causes transaminase elevations (especially with valproate and hepatotoxic drugs), and product content varies widely because supplements are not FDA pre-approved.
- There is no evidence that cannabis or concentrated cannabinoid oils treat cancer; counsel patients away from substituting them for systemic therapy.
6. Pharmacist Counseling Framework & Resources
- Ask without judgment — a structured supplement history belongs in every medication reconciliation, including teas, tinctures, and family remedies.
- Check the interaction first against the specific antineoplastic regimen (CYP3A4 substrates, QTc-prolonging agents, hepatotoxins, narrow-therapeutic-index oral oncolytics).
- Use authoritative references: NCI PDQ Integrative, Alternative, and Complementary Therapies summaries; Memorial Sloan Kettering "About Herbs" database/app; NIH National Center for Complementary and Integrative Health (NCCIH).
- Respect the regulatory reality: under DSHEA (1994), dietary supplements are not FDA pre-approved for safety or efficacy; recommend third-party-verified products (USP or NSF seals) when a patient elects to continue one.
- Document and coordinate — record the product, dose, and decision in the chart and loop in the prescriber; escalate any plan to replace curative therapy to the full care team immediately.
A patient receiving highly emetogenic cisplatin-based chemotherapy asks to replace the prescribed antiemetic regimen with "natural remedies" and asks which complementary approach has guideline-level evidence as an adjunct for chemotherapy-induced nausea. Which response is correct?
Ginger capsules can fully substitute for the 5-HT3 antagonist, NK1 antagonist, and dexamethasone prophylaxis
High-dose intravenous vitamin C during each cycle is the preferred integrative antiemetic
Homeopathic nux vomica preparations have Category 1 evidence for CINV prophylaxis
Acupuncture or acupressure (e.g., P6 point stimulation) is an evidence-supported adjunct that may be added to — never substituted for — the guideline antiemetic regimen
A 54-year-old patient starting definitive cisplatin plus radiation for locally advanced head and neck cancer asks about continuing her daily high-dose supplement regimen (vitamin C 2,000 mg, vitamin E 400 IU, beta-carotene 25,000 IU) "to protect my healthy cells." What should the oncology pharmacist advise?
Discontinue high-dose antioxidant supplements during radiation and ROS-dependent chemotherapy because reactive-oxygen-species scavenging can antagonize treatment efficacy, and beta-carotene/vitamin E supplementation has been linked to increased cancer risk in trials
Continue all three supplements at double doses to maximize the protective antioxidant effect during radiation
Stop only the vitamin C; vitamin E and beta-carotene are proven to radiosensitize tumors
Replace the supplements with laetrile (vitamin B17) 500 mg daily for superior tumor selectivity
A 67-year-old patient with metastatic prostate cancer takes a "hair and nail" supplement containing biotin 10 mg daily. His medical team notes a puzzlingly normal PSA despite radiographic progression, and a recent troponin drawn for chest pain was unexpectedly negative. What is the best pharmacist intervention?
Report the supplement to the FDA as an adulterated product causing hepatotoxicity
Hold the biotin supplement for at least 48-72 hours before laboratory draws, because high-dose biotin interferes with streptavidin-biotin immunoassays, falsely lowering troponin and PSA results
Double the PSA assay frequency, because biotin has no effect on laboratory testing
Substitute collagen peptides and continue laboratory monitoring unchanged
Sections you finish are checked off in the contents.
You've completed this section
Continue exploring other exams